These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 36527474)
1. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD. Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474 [TBL] [Abstract][Full Text] [Related]
2. PPARα mediates night neon light-induced weight gain: role of lipid homeostasis. Luo Y; Yang J; Kang J; Chen K; Jin X; Gonzalez FJ; Liu A Theranostics; 2020; 10(25):11497-11506. PubMed ID: 33052228 [No Abstract] [Full Text] [Related]
3. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease. Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751 [TBL] [Abstract][Full Text] [Related]
4. PPARα is one of the key targets for dendrobine to improve hepatic steatosis in NAFLD. Xu Y; Wang M; Luo Y; Liu H; Ling H; He Y; Lu Y J Ethnopharmacol; 2024 Apr; 323():117684. PubMed ID: 38171466 [TBL] [Abstract][Full Text] [Related]
5. Hepatic Lee YH; Jang HJ; Kim S; Choi SS; Khim KW; Eom HJ; Hyun J; Shin KJ; Chae YC; Kim H; Park J; Park NH; Woo CY; Hong CH; Koh EH; Nam D; Choi JH Elife; 2021 Dec; 10():. PubMed ID: 34964438 [TBL] [Abstract][Full Text] [Related]
6. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice. Lee H; Ahn J; Shin SS; Yoon M Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077 [TBL] [Abstract][Full Text] [Related]
7. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Montagner A; Polizzi A; Fouché E; Ducheix S; Lippi Y; Lasserre F; Barquissau V; Régnier M; Lukowicz C; Benhamed F; Iroz A; Bertrand-Michel J; Al Saati T; Cano P; Mselli-Lakhal L; Mithieux G; Rajas F; Lagarrigue S; Pineau T; Loiseau N; Postic C; Langin D; Wahli W; Guillou H Gut; 2016 Jul; 65(7):1202-14. PubMed ID: 26838599 [TBL] [Abstract][Full Text] [Related]
8. Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. Cui S; Pan XJ; Ge CL; Guo YT; Zhang PF; Yan TT; Zhou JY; He QX; Cheng LH; Wang GJ; Hao HP; Wang H Chin J Nat Med; 2021 Jun; 19(6):401-411. PubMed ID: 34092291 [TBL] [Abstract][Full Text] [Related]
9. Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function. Wang X; Wang J; Ying C; Xing Y; Su X; Men K BMC Pharmacol Toxicol; 2024 Jan; 25(1):7. PubMed ID: 38173037 [TBL] [Abstract][Full Text] [Related]
10. Circadian Rhythm Alteration of the Core Clock Genes and the Lipid Metabolism Genes Induced by High-Fat Diet (HFD) in the Liver Tissue of the Chinese Soft-Shelled Turtle ( Liu L; Liu L; Deng S; Zou L; He Y; Zhu X; Li H; Hu Y; Chu W; Wang X Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397147 [TBL] [Abstract][Full Text] [Related]
11. Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARα. Zhou W; Du Z J Sci Food Agric; 2024 Nov; 104(14):8634-8645. PubMed ID: 38952322 [TBL] [Abstract][Full Text] [Related]
12. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice. Li X; Wang Z; Klaunig JE Toxicology; 2019 Mar; 416():1-14. PubMed ID: 30711707 [TBL] [Abstract][Full Text] [Related]
13. Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy. Yoo J; Jeong IK; Ahn KJ; Chung HY; Hwang YC Metabolism; 2021 Jul; 120():154798. PubMed ID: 33984335 [TBL] [Abstract][Full Text] [Related]